Recombinant Type III Humanized Collagen Solution Attenuates Photoaging: Evidence from In Vitro, In Vivo, and Clinical Studies

Authors:
  • SSSijie Sun
    Sijie Sun
  • KWKeming Wang
    Keming Wang
  • BZBiyao Zheng
    Biyao Zheng
  • CWChenglong Wang
    Chenglong Wang
  • VMVladimir Melnikov
    Vladimir Melnikov
  • XHXiaoming Huang
    Xiaoming Huang
  • QZQiao Zhang
    Qiao Zhang
  • FLFei Liu
    Fei Liu

Abstract
Objective: The efficacy of RhCol III against structural deterioration and pigmentation disorders in photoaged skin remains unclear. This study used a multimodal translational approach to evaluate its biological effects, safety, and efficacy for facial photoaging.Methods: In vitro, cryo-TEM characterized RhCol III self-assembly with naturally secreted collagen, and a keratinocyte–melanocyte co-culture model assessed effects on UV-induced melanogenesis. In vivo, two-photon microscopy assessed dermal structural changes in real time. In a prospective, single-center, single-arm trial, 43 Chinese women (mean age 38.8 ± 6.26 years; Glogau II–III) received three intradermal RhCol III injections at 4-week intervals. Efficacy was assessed up to 24 weeks using GAIS, Atlas grading, VISIA, and biophysical measurements.Results: RhCol III formed biomimetic fibrils with fibroblast-secreted collagens and attenuated UV-induced melanin accumulation (P < 0.05). Two-photon microscopy revealed restoration of dermal collagen and elastic fibers (all P < 0.01). At 4 weeks post-treatment, 39 (100%) subjects were GAIS responders. Periorbital wrinkles, pigmentation, hydration, and erythema improved significantly (all P < 0.05). Treatment was well-tolerated.Conclusion: Intradermal RhCol III injection is safe and effective for photoaging in periorbital and cheek areas, addressing both structural and pigmentary photodamage.